ArticleEndocrinology, diabetes & metabolism2026
Thyroglobulin Autoantibodies Do Not Influence the Outcome of Patients With Differentiated Thyroid Carcinoma.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThyroglobulin (Tg) is a sensitive and specific marker for differentiated thyroid carcinoma (DTC). The presence of thyroglobulin autoantibodies (TgAb) can interfere with Tg measurement in commonly used immunoassays, often resulting in falsely low or undetectable Tg levels. However, data on the prognostic significance of TgAb or its potential utility as a surrogate marker for DTC are limited, leaving its role in the clinical management of DTC uncertain. The aim of this study was the evaluation of the prognostic significance of TgAb in a clinical cohort of patients with DTC.
methodsWe included n = 289 patients with DTC who presented to our clinic for radioiodine treatment. Clinical data and follow-up outcomes were retrospectively analysed. The TgAb status at initial treatment and during follow-up was assessed, and its association with disease remission, persistence or recurrence was evaluated.
resultsRoughly 25% of DTC patients in our cohort showed positive TgAb post-surgery. There were no significant differences between TgAb-positive and TgAb-negative patients in histology, tumour size, metastasis, therapeutic regimen or risk stratification.
conclusionThe presence of TgAb did not influence the outcome regarding overall and disease-free survival. Results implicate that the initial appearance of TgAb does not influence the outcome of patients with DTC. Patients with positive TgAb should be monitored closely during follow-up as Tg measurement is unreliable, while overtreatment should be avoided.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.